Advisory Board - Allinky Biopharma

Go to content

Main menu:

Members of the Board of Directors and Members of the Business Development Board

 

Diego Labarquilla, M. Eng and MBA-INSEAD Business School.
Chairman of the Board, Allinky Biopharma
Mr Labarquilla is President of the Savera Group, a world-wide leader in elevator solutions, and of S21SEC an international company specialized in digital security services. He is also a member of the Board of Directors for many companies operating in different areas of industry and in venture capital. He began his professional career at Colgate Palmolive but soon relocated to Fontainebleau (France), to follow the MBA Program at the INSEAD Business School. Later, he was responsible for the international expansion of Savera as its Managing Director, which today has production centers in Brazil, Germany, China and India. He has also been very active as a venture capitalist funding companies in many fields, such as ICTs, biotechnology, services and discrete manufacturing.


Manuel López-Figueroa, PhD, is a Vice President at Bay City Capital and has been with the firm since July 2001. He specializes in evaluating investment opportunities with an emphasis on CNS. In addition, Dr. López is the Scientific Liaison for the Pritzker Neuropsychiatric Disorders Research Consortium, a collaborative research enterprise comprised of a group of leaders in psychiatry, neuroscience and genetics from Stanford University, University of Michigan, Cornell University and the Universities of California at Davis and Irvine. The consortium aims to discover the neurobiological and genetic determinants of mood disorders and schizophrenia with the goal to develop novel diagnostics and therapeutics. Dr. López is responsible for planning and directing all aspects of the consortium including strategy, R&D, legal (IP & contracts) and financial, to facilitate the commercialization of discoveries to fund additional research. Dr. López has over 15 years of experience in the field of Neuroscience, has won numerous awards during his academic research career, and has published extensively. He completed post-doctoral work at the University of Michigan and at the University of Copenhagen, Denmark. Dr. López received a PhD in Medicine and Surgery, and a MS in Molecular and Cell Biology from the Universities of Las Palmas and La Laguna, Spain, respectively.


Robert M. Elfont, Ph.D., MD, Johns Hopkins-trained neurologist with subspecialty training in neuroimmunology and neurovirology. Over ten years in the pharmaceutical and biotechnology industry. Eight years in academic practice. Knowledgeable in all phases of clinical development. Extensive expertise in CNS drug development, including neurologic (multiple sclerosis, Alzheimer’s disease, stroke, Parkinson’s disease, epilepsy), psychiatric (schizophrenia, depression, substance abuse), and pain (neuropathic pain, fibromyalgia, painful diabetic neuropathy) indications. Experience with small molecules, biologics, and devices. Rob is currently the managing partner at Strategic Clinical Development LLC and previouly held top executive positions in Avigen, Roche, Pfizer and Teva.
 


Other Board members will be soon appointed

 
Back to content | Back to main menu